secwatch.observer — SEC 8-K summary
======================================

Issuer:     PACS Group, Inc. (PACS)
CIK:        0002001184
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0002001184-25-000031
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

PACS Group restates Q1-Q2 2024 revenue; overstatement estimated at $61-65M
--------------------------------------------------------------------------

- Audit Committee concludes Q1 2024 and Q2 2024 financials should no longer be relied upon.
- Revenue overstated by $15-17M for Q1 2024 and $46-48M for Q2 2024 due to Medicare Part B respiratory and therapy billing.
- Restatement linked to compliance uncertainties and revenue recognition under ASC 606; material weaknesses expected.
- Audit Committee investigation nearing completion; no integrity issues found for CEO, CFO, or CAO.
- Company remains delinquent on Q3 2024, FY 2024, and Q1 2025 filings; NYSE extended compliance deadline to Sept 2, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2001184/000200118425000031/0002001184-25-000031-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2001184/000200118425000031/pacs-20250612.htm
  HTML page:      https://secwatch.observer/filing/0002001184-25-000031

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer